Summary An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) (Klingebiel et al, 1989; Garaventa et al, 1991) . Although treatment of neuroblastoma with ['311I]MIBG has been shown to be efficacious, improvements in this therapeutic modality are needed and a number of approaches are under active investigation. For example, combination of [311I]MIBG treatment with high-dose chemotherapy and total body irradiation is being pursued (Gaze et al, 1995) . For micrometastases, the long-range 3-particles of 'l3I are suboptimal (Sisson et al, 1990; O'Donoghue et al, 1991) and the development of an MIBG analogue labelled with an a-emitter such as 7.2 h half-life 21'At has been advocated (Shapiro et al, 1987; Mairs et al, 1991 (Vaidyanathan and Zalutsky, 1992; Vaidyanathan et al, 1994a) . In clonogenic assays with the SK-N-SH human neuroblastoma cell line, the Do value for
[211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nm respectively, suggesting that the affinities of these tracers for the noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [2l1At]AFBG was seen in vivo in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of
[21lAt]AFBG towards in vivo dehalogenation was less than that of [2llAt]MABG, as evidenced by the higher uptake of 21'At in thyroid, spleen, lungs and stomach.
Keywords: neuroblastoma; meta-iodobenzylguanidine; 3-[211At]astato-4-fluorobenzylguanidine Iodine-131-labelled meta-iodobenzylguanidine ([311I]MIBG) has been used for the targeted radiotherapy of a number of neuroendocrine tumours, such as neuroblastoma (Klingebiel et al, 1989 ; Garaventa et al, 1991) . Although treatment of neuroblastoma with ['311I ]MIBG has been shown to be efficacious, improvements in this therapeutic modality are needed and a number of approaches are under active investigation. For example, combination of [311I]MIBG treatment with high-dose chemotherapy and total body irradiation is being pursued (Gaze et al, 1995) . For micrometastases, the long-range 3-particles of 'l3I are suboptimal (Sisson et al, 1990 ; O'Donoghue et al, 1991) and the development of an MIBG analogue labelled with an a-emitter such as 7.2 h half-life 21'At has been advocated (Shapiro et al, 1987; Mairs et al, 1991) .
We developed a method for the synthesis of meta-[211At]astatobenzylguanidine ([21'At]MABG) and preliminary studies showed that this compound behaved in a similar fashion to MIBG (Vaidyanathan and Zalutsky, 1992; Vaidyanathan et al, 1994a) . In clonogenic assays with the SK-N-SH human neuroblastoma cell line, the Do value for
[21At]MABG was 0.2 kBq mll compared with 384 kBq ml-for no carrier added (n.c.a.) ['311 ]MIBG, indicating a more than 1000-fold greater cytotoxicity for the cx-particle-emitting analogue over ['311] MIBG under single-cell conditions (Strickland et al, 1994) .
Recently, a fluorine-containing analogue of MIBG was developed for positron emission tomography (Vaidyanathan et al, 1994b; . This agent, 4-fluoro-3-iodobenzylguanidine (FIBG; Figure  1 ), also could be labelled with iodine radionuclides (Vaidyanathan et al, 1996) . The uptake and retention of FIBG in SK-N-SH human neuroblastoma cells in vitro and mouse target tissues (heart and adrenals) were significantly higher than those of MIBG. Encouraged by the exquisite cytotoxicity delivered by [2"'At]MABG, an astatinated analogue of FIBG also was synthesized (Vaidyanathan et al, 1996) in normal, uptake-1-containing tissues (heart and adrenals) in mice.
MATERIALS AND METHODS General
All chemicals were purchased from Aldrich Chemical Company except as noted. Unlabelled MIBG, desipramine (DMI) and noradrenaline (arterenol; NE) were obtained from Sigma. Sodium 3-astato-4-fluorobenzylguanidine 227 
Preparation of radiohalogenated benzylguanidines
Meta-iodobenzylguanidine (Vaidyanathan and Zalutsky, 1993) and 4-fluoro-3-iodobenzylguanidine (Vaidyanathan et al, 1996) were labelled with 1311 at the no-carrier-added level, following procedures reported previously. Briefly, to the required amount of ['31'] iodide in 1-3 pl of 0.1 N sodium hydroxide was added 10 ,l of 0.3 M solution of N-chlorosuccinimide in trifluoroacetic acid followed by the corresponding silicon precursor in trifluoroacetic acid (5 ,l of 0.1 M solution). After 5 min at room temperature, the product was isolated by reversed-phase chromatography. The 2'At activity was produced on the Duke University CS-30 cyclotron via the 209Bi(a, 2n)2'At reaction by bombarding natural bismuth metal targets with 28-MeV a-particles (Zalutsky et al, 1989; Larsen et al, 1996) . The activity was isolated from the target by dry distillation into either 0.1 N sodium hydroxide (0.1 ml) or chloroform (0.5 ml). The activity trapped in 0.1 N sodium hydroxide was concentrated to less than 3 gl, or the activity trapped in chloroform was extracted in more than 95% efficiency into 3 pl of 0.1 N sodium hydroxide for the preparation of astatinated benzylguanidines. To the activity obtained as above in a Reacti vial was added 10 ,l of N-chlorosuccinimide and the corresponding precursor solutions in trifluoroacetic acid, as described for the iodination reactions. The reaction mixture was heated at 70°C for 5 min and 12 min, for [2"'At]MABG (Vaidyanathan and Zalutsky, 1992) and [2l'At]AFBG (Vaidyanathan et al, 1996) preparation respectively, and the products were isolated by reversed-phase chromatography.
No co-eluting mass peak was detected in the UV trace of HPLC analyses of any of these radiolabelled benzylguanidines. To date, a maximum of at least 37 MBq of each tracer has been produced.
Since the detection limit of iodobenzylguanidines is about 1 nmol, the specific activities of radiohalogenated benzylguanidines is expected to be greater than 37 TBq mmol-1. As there are no stable isotopes of astatine, a specific activity nearer the theoretical limit (16 000 TBq mmol-') is more likely for the astatinated agents.
Measurement of radioactivity
A dose calibrator (Capintec, CRC-7R, USA) for higher amounts of activity and an automated gamma counter (LKB 1282, Wallac, Finland) for lower count rates were used. For measurement of 2"'At activity using the gamma-counter, the energy window was set to encompass the Po K X-rays emitted by its electron capture decay branch. In the dose calibrator, the window was set to that of '33Xe. Both gamma-counter and dose calibrator had been crosscalibrated for 2'At with a germanium semiconductor detector. For paired-label studies, gamma-counter counting windows were set to a dual-channel to encompass the 77-92 keV Po X-rays emitted by '"At and the 364-keV gamma-rays of "3'I. Counting data were automatically corrected for the 11% crossover of 1311 in the 2"'At gate and the physical decay of both nuclides.
Cells and culture conditions
The human neuroblastoma cell lines SK-N-SH (uptake-1 positive) and SK-N-MC (uptake-I negative) (Biedler et al, 1973) were purchased from American Type Culture Collection (Rockville, MD, USA). The incubation medium (JRH Biosciences, Lenexa, KS, USA) was made by mixing 440 ml of RPMI-1640, 50 ml of Serum Plus, 5 ml of penicillin-G/streptomycin (5000 U of penicillin and 5000 ,tg of streptomycin in 1 ml) and 5 ml of glutamine (200 mm 
DISCUSSION
An important factor in the optimization of endoradiotherapy is to match the properties of the emitted radiation with the characteristics of the tumour target. For micrometastatic disease, the radionuclide British Journal of Cancer (1997) 76 (2), 226-233 2"At is particularly appealing since its a-particles deposit their energy over a range equivalent to only a few cell diameters. In addition, these a-particles are radiations of high linear energy transfer with a relative biological effectiveness higher than p-particles, such as those emitted during the decay of '3'I. This has led a number of investigators to suggest that a 2"'At-labelled analogue of ['311 ]MIBG might be a more effective agent for the treatment of neuroblastoma (Shapiro and Gross, 1987; Kemshead et al, 1990; Mairs et al, 1991 (Strickland et al, 1994) . The results obtained in vitro with [211At]MABG have been highly encouraging; however, other 2"'At-labelled MIBG analogues may have even more favourable properties as endoradiotherapeutic agents. While rapid uptake of [211At]MABG in human neuroblastoma cell lines was achieved, rapid washout was also observed, particularly in the SK-N-SH line, in which a retention half-life of 5-6 h was seen (Strickland et al, 1994) . Recently, we have reported that substitution of a fluorine atom ortho to the iodine in MIBG resulted in an MIBG analogue, ['311 ]FIBG, with modestly increased binding, but significantly enhanced retention of radioiodine in SK-N-SH cells in vitro (Vaidyanathan et al, 1997 If [21 'At] AFBG is to be pursued as an endoradiotherapeutic agent, it is critical to understand the mechanisms responsible for its uptake not only in human tumour cells, but also in normal tissues such as heart and adrenals, where uptake-1-mediated localization could be problematical. In SK-N-SH cells, MIBG is taken up by a neuron-specific active uptake-I mechanism (Buck et al, 1985; Smets et al, 1989) , a process that has been demonstrated to occur with the analogues [21 'At]MABG (Vaidyanathan and Zalutsky, 1994a) , ['8F ]FIBG (Vaidyanathan et al, 1994b (Vaidyanathan et al, , 1995 and ['311 ]FIBG Vaidyanathan et al, 1997) .
The results of this study suggest that the uptake-I mechanism is also responsible for the accumulation of [211At]AFBG in SK-N-SH neuroblastoma cells. The tricyclic antidepressant DMI, norepinephrine, MIBG and FIBG all in the heart and adrenals of mice pretreated with the uptake-1 inhibitor DMI, albeit to a slightly lesser degree than that reported for MIBG and other halobenzylguanidine analogues (Vaidyanathan et al, 1995; Valette et al, 1993) . Taken together, these results suggest that substitution of astatine for iodine in the FIBG molecule does not interfere with the uptake-1 mechanism responsible for the accumulation of halobenzylguanidines in this human neuroblastoma cell line.
Differences in the mechanism of tracer uptake between stability of a variety of pharmaceuticals (Barnette, 1984) . With regard to our particular application, as fluorine is the most electronegative element, its presence could stabilize weaker adjacent carbon-halogen bonds (Goldman, 1969 (Servidei et al, 1995) or changes in the intracellular storage site. The affinity of four halobenzylguanidines for the uptake transporter is indeed different, as shown by the IC 5 values of MIBG for their inhibition.
Decreasing the loss of label from an endoradiotherapeutic agent is important not only for maximizing radiation absorbed dose to tumour, but also for minimizing deleterious effects to normal tissues. MIBG is considered to be metabolically stable (Mangner et al, 1986) ; however, paired-label studies in normal mice have demonstrated that thyroid uptake of radioiodine following administration of ['311]FIBG was 2-3 times lower than that from ['251 ]MIBG, suggesting an enhanced inertness to deiodination for the former (Vaidyanathan et al, 1997) . Based on these results, we anticipated that substitution of a fluorine atom ortho to the astatine would decrease the rate of deastatination as well.
The relative selectivity of astatide for spleen and lungs is about ten times higher than that for iodide (Garg et al, 1990) , so accumulation of activity in these tissues following paired injection of 21At-and '311-labelled analogues is consistent with deastatination in vivo. When the tissue distribution of [211At]AFBG and ['311]FIBG was compared, uptake of both radionuclides in the lungs was quite similar and no consistent trend was observed with regard to 211At/'311 spleen uptake ratios. However, the accumulation of [21 At]AFBG in the spleen, lungs, thyroid and, barring a few, in most other tissues was higher than that seen for [21 'At]MABG. This could reflect a general effect of fluorine substitution, analogous to the increased tissue retention of FIBG compared with MIBG (Vaidyanathan et al, 1997) , or a greater susceptibility of [21 'At]AFBG to deastatination. Although the latter is a distinct possibility, it is difficult to explain why ortho substitution of a fluorine for a hydrogen could decrease the rate of deiodination but increase the rate of deastatination. Labelled catabolite analyses will be performed in order to investigate further the nature of these differences.
In summary, the results of this study demonstrate that the uptake 
